HBL Hadasit Bio Holdings

HBL Hadasit Bio Holdings is a publicly traded holding company based in Jerusalem that gives public investors direct exposure to a curated portfolio of biotech assets originating from Hadassah Medical Center. The structural setup is unusual: the firm acts as both an investor and a publicly listed pass-through to clinical-stage assets coming out of one of Israel’s largest academic medical centers. Founders working with Hadassah-linked technologies have a natural pathway here.

Stages span Seed, Series A, and Series B, with check sizes between $1 million and $5 million. Sub-verticals are biotech and pharma. The record does not list specific portfolio companies in the source data. Activity is concentrated in Israel and is heavily anchored on Hadassah-originated science.

For founders, the practical entry point is almost always a connection to Hadassah Medical Center or its tech transfer office. Healthcare AI teams without a Hadassah research linkage will find the firm structurally less relevant. Therapeutic and diagnostic assets emerging from the medical center are the natural fit. Founders should also understand the public-company dimension: HBL is subject to disclosure obligations, which can affect the timing and confidentiality of deal information. This is most useful for founders comfortable operating inside a publicly visible portfolio structure rather than a private-only fund.